Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. 30 March 2021. Eli Casdin.

Executive Summary

Blank-check company CM Life Sciences II signed an agreement to merge with proteomics company SomaLogic, a deal valued at $1.25bn. See what Eli Casdin, CEO of CM Life Sciences II said about it here.

“The long-promised power of proteomics is quickly becoming a commercial and clinical reality, and in our view, SomaLogic is the leading platform in the field. What is needed is to accelerate this transformation from promise to reality is human and financial capital, and the CMS II team could not be more honored to provide both through this merger.” – Eli Casdin, CEO, CM Life Sciences II

Click here for a free trial of Medtech Insight

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts